Once-monthly oral PrEP moves into late-stage trials
Engineered T-cells may kill off reservoir cells, mimicking elusive CD8 vaccine effect
Resistance is a growing concern amid rising use of doxyPEP
“We will not go back!”: a powerful, resolute response to funding cuts at IAS 2025
Rwanda’s HIV leadership on display at IAS 2025
Coming soon: news from IAS 2025
Are automated campaigns driven by AI the future of HIV prevention?
Two doses of HPV vaccine as effective as the recommended three-dose schedule for women with HIV
Women with HIV have no cardiovascular advantage over men, unlike in the general population
